The c-fos gene is rapidly and transiently activated in quiescent BALB/c-3T3 cells in response to serum, platelet-derived growth factor or conditioned medium from v-sis-transformed cells. This activation occurs at the level of transcription and in the absence of new protein synthesis. Using a gel electrophoresis DNA-binding assay, we have found a DNA-binding activity in BALB/c-3T3 cells that is induced within 20 min of treatment with conditioned medium from v-sis-transformed cells. A DNA methylation interference assay has shown that this factor binds to a sequence approximately 346 base pairs upstream of the transcription initiation site of the human c-fos gene. Insulin, epidermal growth factor, and phorbol 12-myristate 13-acetate fail to induce this DNAbinding factor. Protein synthesis inhibitors do not block the induction of this activity. We propose that this factor preexists in an inactive form in quiescent cells and that its binding activity is activated in response to appropriate extracellular inducers.
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Polypeptide growth factors that bind to cell surface receptors can promptly regulate specific gene transcription in the nucleus (1, 2) . The induction of gene expression by growth factors is required for the mitogenic response (3, 4) . However, the biochemical details of the signaling pathways that lead from the receptor to the activation of specific gene transcription in the nucleus are incomplete. Many oncogenes are derived from cellular genes that encode components of growth factor-regulated signal transduction pathways. Some oncogenes themselves, such as v-sis, encode growth factors (5) . Other oncogenes, such as v-erbB and v-fms, appear to encode parts of growth factor receptors (6, 7) . The ras family of oncogenes encodes proteins that bear striking similarity to the guanine nucleotide-binding proteins that are involved in receptor-mediated signal transduction at the membrane (8) . The expression of still other oncogenes, such as c-myc and c-fos, is regulated by the binding of growth factors to cell surface receptors (9) (10) (11) (12) (13) . Thus, it is clear that the chronic activation of growth factor-regulated metabolic pathways by oncogenes is an important step in cell transformation. However, it is as yet unclear which of the many immediate intracellular responses to growth factors lead to the activation of transcription.
Within minutes of growth factor addition to cells, changes such as autophosphorylation of the receptor, an increase in phosphatidylinositol turnover, a rise in intracellular pH and Ca2" concentration, and a rearrangement of actin cables can be observed (2) . Any or all of these events could transmit signals to nuclear proteins that regulate gene transcription. Alternatively, the receptor, or fragments thereof, could be internalized, migrate to the nucleus, and activate specific genes.
One approach to dissecting the signal transduction pathway is to start at the level of the gene and then attempt to trace the signaling pathway backward, out to the cytoplasm. This approach has several advantages over working from the cytoplasm inward. One is that the starting point, the activation of new gene transcription, is an event that is known to be important for the mitogenic response to growth factors (3, 13) . A second advantage is that in retracing the pathway, important target substrates for protein kinases might be identified. Growth factors activate many cellular kinases, each of which has many substrates (2) . Identifying the substrates for a given protein kinase and then determining which substrate is critical for nuclear signaling is a formidable task. It should be easier to identify a potential kinase for a given phosphoprotein substrate than vice versa.
To initiate this type of analysis, we have studied the regulation of the cellular fos gene. c-fos is promptly and transiently induced by platelet-derived growth factor (PDGF) (12) (13) (14) . As judged by nuclear run-off transcription assays, c-fos transcription starts to increase within 5 min of PDGF addition to BALB/c-3T3 cells (13) . medium was changed to DME medium/5% human plateletpoor plasma (21) . Experiments were initiated the following day.
Murine epidermal growth factor (receptor grade) was obtained from Collaborative Research (Waltham, MA). Porcine insulin, phorbol 12-myristate 13-acetate (PMA), and cycloheximide were obtained from Calbiochem. Anisomycin was obtained from Sigma. v-sis-conditioned medium (SCM) was produced from a NRK-simian sarcoma virus (SSV) nonproducer cell line (22, 23) . NRK-SSV cells were grown to confluence in DME medium/10% bovine calf serum, washed, and incubated for 48 hr in DME medium alone. At a 1-to 2-fold concentration, this medium gave a maximum induction of c-fos gene expression and replicative DNA synthesis in BALB/c-3T3 cells. All additions were made onto cells in DME medium/5% human platelet-poor plasma.
Plasmids and Probes. All fos sequences used were subcloned out of the human genomic c-fos clone pc-fos-human-1 (ATCC 41042) into the vector pGEM1 (Promega Biotec, Madison, WI). The 585-bp fragment extending from the Xho I site at -711 to the Xma III site at -126 was subcloned between the Sal I and Sma I sites of pGEM1. Digestion of this plasmid with Pst I liberates a 352-bp fragment extending from the Pst I site at -361 to the Pst I site upstream of the Sal I-Xho Ijunction in the polylinker. This is fragment B (Fig. 1) . The 235-bp fragment extending from the Pst I site at -361 to the Xma III site at -126 was subcloned between the Pst I and the Sma I sites of pGEM1. Digestion of this plasmid with Hind1II and EcoRI liberates the entire insert and polylinker. This is fragment A (Fig. 1 ). Fragment C is the 250-bp EcoRI-BstNI fragment of pGEM1. The end-labeled probe, which includes the 96-bp Pst I-BstNI fragment from -361 to -265, was prepared by labeling the Pst I-Xma III subclone at the HindIII site next to the Pst I site in the polylinker, either using reverse transcriptase and [a-32P]dNTPs or using polynucleotide kinase and [y32P]ATP. Digestion with BstNI liberated a 109-bp radiolabeled fragment, which was electrophoretically purified and used as a probe in band-shift assays as described below.
Whole-Cell Extracts. Whole-cell extracts were prepared according to Manley et al. (24) . All operations were performed at 4TC. In brief, cells were harvested in phosphatebuffered saline and pelleted. The cell pellet was resuspended in 4 packed-cell volumes of 10 mM Tris, pH 7.9/1 mM EDTA/1 mM dithiothreitol, and the cells were incubated 20 min on ice. The swollen cells were homogenized eight strokes in a Dounce homogenizer with a type B pestle and mixed with 1 packed-cell volume of 50 mM Tris, pH 7.9/10 mM MgCl2/1 mM dithiothreitol/25% (wt/vol) sucrose/50% (vol/vol) glycerol. One packed-cell volume of saturated (NH4)2SO4 was added dropwise while the mixture was stirred, and it was stirred an additional 30 min. The mixture was centrifuged for 3 hr at 43,000 rpm in an SW50.1 rotor. The upper 90% of the supernatant was collected and 0.33 g of (NH4)2SO4 was added per ml of fluid. The mixture was stirred an additional 30 min after the salt had dissolved. The mixture was centrifuged for 20 min at 11,000 rpm in an SS-34 rotor, and the pellet was dissolved in 1 packed-cell volume of 10 mM Hepes, pH 7.9/100 mM KCl/1 mM EDTA/1 mM dithiothreitol/20% glycerol/0.5 mM phenylmethylsulfonyl fluoride. The solution was dialyzed against two changes of 100 volumes each of the same buffer. The extract was divided into aliquots and was stored at -80°C. Frozen extracts retained binding activity for at least 6 months. Protein concentrations were determined by the Bio-Rad protein assay.
Gel Electrophoresis DNA-Binding Assay. Whole-cell extracts were used for band-shift assays essentially as described by Carthew et al. (25) . In brief, the end-labeled probe (0.15 ng, 7000 dpm), whole-cell extract, and 1 jig of poly(dIdC)-poly(dI-dC) were incubated for 30 min at 30'C in a final volume of 10-15 1.l of 10 mM Hepes, pH 7.9/50 mM NaCI/1 mM dithiothreitol/1 mM EDTA/10% (vol/vol) glycerol. Competitor DNAs and the labeled probe were added to the binding reaction simultaneously. Samples were layered onto 4% acrylamide gels (acrylamide/bisacrylamide, 80:1) and electrophoresed at 10 V/cm in 6.7 mM Tris HCl, pH 7.9/3.3 mM sodium acetate/1 mM EDTA, with buffer recirculation between the electrode chambers at 50 ml/min. Gels were fixed in 10% acetic acid/10% methanol, dried, and exposed to x-ray film.
Methylation Interference of Binding. The end-labeled probe was treated with dimethyl sulfate according to Maxam and Gilbert (26) . Methylated probe was incubated with whole-cell extract prepared from cells treated with SCM for 30 min. The sample was electrophoresed as above, and the wet gel was exposed to x-ray film. Individual bands were excised from the gel, and the radiolabeled DNA was isolated by electrophoresis onto an NA45 membrane (Schleicher & Schuell) in the presence of 0.1% sodium dodecyl sulfate. Radiolabeled DNA from each band was cleaved with piperidine (26) and fractionated on a sequencing gel. The identity of methylated residues was confirmed by dideoxy chain-termination sequencing.
RESULTS
To identify specific DNA-binding proteins, we have used the sensitive band-shift technique (25) (26) (27) (28) (29) . This assay takes advantage of the fact that a protein-DNA complex will migrate with a characteristically slower mobility than a free DNA fragment when electrophoresed through a low-ionicstrength polyacrylamide gel. Thus, when unfractionated nuclear or whole-cell extracts are incubated with end-labeled DNA fragments and electrophoresed through the appropriate gel system, a series of bands appears that migrate more slowly than free DNA. Some of the bands seen on such gels are due to nonspecific DNA binding proteins. Such nonspeciflic binding can be reduced by including simple-sequence carrier DNA such as poly(dI-dC)-poly(dI-dC) in the binding reaction mixture. Bands representing specific DNA binding can be identified by virtue of the fact that their intensity is decreased by adding excess homologous, but not excess nonhomologous, DNA to the binding reaction.
The results of a band-shift gel where a DNA probe extending from positions -361 to -265 of the c-fos promoter has been incubated with extracts of growth factor-treated BALB/c-3T3 cells are shown in Fig. 1 plexes B1 and B2 and from the free probe. These DNAs were cleaved with piperidine and electrophoresed through DNA sequencing gels. The resulting autoradiograph gives a pattern of bands corresponding to guanine residues in the sequence. Some adenine residues are also partially methylated. Where methylation of a guanine residue has interfered with the binding of the factor to the probe, the lanes with the bound peat, or the y-fibrinogen promoter. This result indicates that this factor is not a general transcription factor but has specificity for the c-fos gene. Some of the lower bands in Fig.  1 are also affected by specific competitor DNAs. However, they are not consistently observed in different extract preparations and do not bind to an oligonucleotide containing the binding site of the B1 and B2 complexes.
Since c-fos transcription is induced by growth factors, we looked for inducibility of this DNA-binding activity. Conditioned medium from v-sis-transformed cells induces the appearance of this binding activity as shown in Fig. 2 . This medium contains a v-sis-encoded protein which is similar to PDGF in that it binds to the PDGF receptor, has mitogenic activity, and reacts with anti-PDGF antibody (22, 23, 30, 31 By using a methylation-interference assay, we have been able to identify the site where this factor binds the c-fos DNA fragment (20) . The results of this experiment are shown in Fig. 3 . The -361 to -262 fragment of the c-fos promoter was partially methylated by reaction with dimethyl sulfate. This end-labeled, methylated DNA was used to run a preparative band-shift gel. Labeled DNA was then isolated from com- and B2 complexes (see Fig. 1 ).
complexes have a diminished guanine band relative to the lane with the free probe. From Fig. 3 , it can be seen that this factor binds to the sequence, 5'-CCCGTC-3', located at position -346 of the c-fos gene. All the methylated guanine residues of both DNA strands interfere with factor binding at this site. Two additional adenine residues may also be involved at the binding site. The interference pattern is the same for both the B1 and B2 complexes. Evidence of interference of binding was detected only at this sequence and at no other location in the probe. To further confirm that this sequence is the factor binding site, a pair of complementary 21-residue oligonucleotides including 15 residues of the c-fos sequence spanning the region of methylation interference was synthesized. This synthetic fragment specifically competes with the probe for B1 and B2 complex formation as shown in Fig. 4 . A competitor oligonucleotide made homologous to a sequence of the probe that does not show methylation interference fails to compete with the probe for this binding. The oligonucleotide that contains the binding site will also specifically bind to the inducible factor when it is used directly as the labeled probe in the gel-shift assay (data not shown). The 6-bp sequence, CCCGTC, is not necessarily sufficient for factor binding. Because the methylation interference assay primarily detects guanine residues at contact sites, the actual binding-recognition site is likely to include some ART pairs flanking this central hexamer.
The induction of this c-fos binding factor is inducer specific. Band-shift assays done with extracts from confluent, quiescent BALB/c-3T3 cells treated with EGF, insulin, the tumor promoter PMA, or SCM are shown in Fig. 5A . Only the SCM-stimulated cells appear to contain the B2-complex binding activity. Heat-treated platelet extracts (32) , which contain significant amounts of PDGF, also induce the appearance of this binding activity (data not shown). Control experiments show that another DNA-binding factor which binds to the -320 to -299 c-fos sequence shows less than a 2-fold change in binding activity when quiescent cells are treated with SCM, PMA, or epidermal growth factor (see Discussion). It is not surprising that extracts from insulin-or epidermal growth factor-treated cells fail to contain the inducible c-fos DNA-binding activity since these agents do not induce transcription of the c-fos gene under the conditions of this experiment (13) . However, the tumor promoter PMA does induce the c-fos gene at the transcriptional level (13, 33) to an extent similar to that seen with SCM or platelet extracts. There are at least two interpretations of this result. One is that PMA induces this factor only slightly and that it is below the threshold level of detection. A second possibility, which we favor, is that PMA acts by way of another DNA-binding activity that can activate an enhancer located elsewhere in the c-fos locus. Fig. 5B shows that the fos promoter binding activity is inducible even in the absence of protein synthesis. BALB/c-3T3 cells were treated with both SCM and cycloheximide (10 Ag/ml). Under these conditions, protein synthesis is inhibited by >90% and the rate of c-fos transcription is superinduced by 10-fold (ref. 15 and unpublished results), whereas scanning densitometry measures only a 2-fold superinduction in c-fos binding activity. Similar results are obtained using anisomycin as a protein synthesis inhibitor (>95% inhibition of protein synthesis). This result, coupled with the rapid time course of induction, suggests that the factor preexists in quiescent cells and is not newly synthesized after growth factor treatment. Thus, it is likely that SCM addition to the cells stimulates a conversion of the factor from an inactive to an active DNA-binding form through an as yet unknown mechanism. In addition, this experiment indicates that the superinduction of transcription caused by cycloheximide cannot be quantitatively accounted for by a corresponding increase in the level of this DNA-binding activity. Treisman (34) has shown that the -320 to -299 fragment of the human c-fos gene is sufficient to restore serum inducibility to an uninducible deletion mutant of the c-fos promoter.
Gilman et al. (18) and Treisman (34) have found a constitutive factor from HeLa and WEHI-231 cells that binds to the palindromic sequence in this fragment. However, the -320 to -299 fragment does not bind to the SCM-inducible factor suggesting that the -346 site is not required for serum induction offos. Experiments that we have performed with BALB/c-3T3 cell extracts confirm that the -320 to -299 binding factor is constitutively present while the -346 factor is induced by SCM (data not shown). It seems unlikely that the -346 sequence is not involved in the regulation of c-fos since it binds to an inducible factor and shows absolute conservation between human and mouse (17, 35) . A possible explanation for the functions of this sequence could lie in the fact that the c-fos gene is capable of responding to a wide range of external stimuli including serum, PDGF, epidermal growth factor, nerve growth factor, membrane depolarization, PMA, poly(rI-rC), and Ca2l influx (10, 11, 13, 36, 37) .
Each of these agents, rather than activating the same enhancer element in the c-fos gene, could activate an independent responder element or set of elements. This implies that c-fos transcription is controlled by multiple independent enhancer elements, each activated by distinct signals. Our observation that PMA does not induce the -346 binding factor but does activate c-fos transcription is consistent with this idea. PMA induction offos could be mediated through a sequence elsewhere in the c-fos locus.
The inducible DNA-binding factor which we have found may be an intermediate in the signaling pathway which couples a cell surface receptor to specific gene regulation in the cell nucleus. As such, it is potentially a substrate for growth factor-regulated protein kinases and may be useful in elucidating the metabolic pathways which lead from the cell surface to the nucleus.
